Skip to content

HRB

ERA4Health IICS4all 2027

Up to €650,000 per grant (HRB contribution); up to €1,500,000 total HRB commitment to the call| Deadline: 14 January 2027 (in 55 days)|Up to 48 months

11:00 GMT (12:00 CET); ECRIN engagement deadline 30 November 2026

Last seen in a scan/import: .

Catalog updated: .

These timestamps are not source verification. Confirm the current deadline and your eligibility on the funder’s call page before applying.

Closes 14 Jan 2027. Add it to your calendar, then see what else you're eligible for. Check my fit for this call →

ERA4Health IICS4all 2027 funds multi-national, investigator-initiated phase III randomised controlled trials in cardiovascular, autoimmune, metabolic or non-communicable respiratory disease, including comparative-effectiveness and drug repurposing studies. HRB contributes up to €650,000 per grant to Irish partners within a multi-country consortium, as part of a wider €1.5 million commitment to this one-off call. Cancer, basic/pre-clinical research and commercial-purpose trials are excluded, and Host Institutions in Northern Ireland are not eligible.

Details

Funder HRB
Budget Up to €650,000 per grant (HRB contribution); up to €1,500,000 total HRB commitment to the call
Deadline 14 January 2027
Duration Up to 48 months
Consortium Required — multi-national consortium of Partners across participating countries, with a single Host Institution/Lead Applicant contracted per country; additional associate partner clinical sites permitted
Application 2-stage: joint pre-proposal → invited full proposal (budget/deliverables submitted by Irish partners)
Frequency One-off
Eligible countries IE

Eligibility & scope

Supports multi-national investigator-initiated phase III randomised controlled clinical studies (comparative-effectiveness or drug repurposing) in cardiovascular, autoimmune, metabolic or non-communicable respiratory diseases, including underrepresented populations. Not open to Host Institutions in Northern Ireland; excludes cancer, basic/pre-clinical research, and commercial-purpose trials; joint proposal must be submitted in English.

Who Should Apply

  • •Investigators leading multi-national phase III randomised controlled trials
  • •Irish-based Host Institutions/Lead Applicants partnering with teams across participating countries
  • •Researchers in cardiovascular, autoimmune, metabolic or non-communicable respiratory disease
  • •Comparative-effectiveness or drug repurposing trial designs, including underrepresented populations
  • •Not applicable to Host Institutions in Northern Ireland

Key Dates

  • •Pre-proposal deadline 14 January 2027, 11:00 GMT (12:00 CET)
  • •ECRIN engagement deadline 30 November 2026
  • •Two-stage process: joint pre-proposal then invited full proposal; up to 48-month project duration

Tips for Applicants

  • ✓Engage with ECRIN well before the 30 November 2026 deadline if clinical trial infrastructure support is needed for the consortium.
  • ✓Confirm each country's Host Institution/Lead Applicant arrangement early, since only one is contracted per country alongside associate clinical sites.
  • ✓The joint proposal must be submitted in English even though HRB funds only the Irish partner's budget and deliverables at full-proposal stage.

Frequently Asked Questions

How much funding does ERA4Health IICS4all 2027 provide?

HRB contributes up to €650,000 per grant to Irish partners, with up to €1.5 million total committed by HRB to this call.

What diseases does this call fund research on?

It funds phase III randomised controlled trials in cardiovascular, autoimmune, metabolic or non-communicable respiratory disease; cancer and basic/pre-clinical research are excluded.

Is a consortium required for this grant?

Yes, a multi-national consortium of partners across participating countries is required, with one Host Institution/Lead Applicant contracted per country.

Can Northern Ireland institutions apply?

No, Host Institutions in Northern Ireland are not eligible for this call.

How long can an ERA4Health IICS4all project run?

Projects can run for up to 48 months.

clinical-trialscardiovascular-diseaseautoimmune-diseasemetabolic-diseaserespiratory-diseasehrbconsortium-requiredphase-iii-trial
View full call →

Summary generated by AI based on published grant information. Always verify details on the funder's website.

Similar grants

Browse all open grants →

Browse Related

Could ERA4Health IICS4all 2027 be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →